20 October 2020
Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.
Clinical researchers at Oxford University announce new collaboration with Janssen to detect blood cancers sooner
8 August 2019
The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.
30 June 2017
Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.